Abstract Objective
Hereditary neuropathies form a group of genetic disorders with a broad range of phenotypes, mode of inheritance and causative genes. The objective of this study is to identify the genetic cause of disease in a congenital form of distal hereditary motor neuropathy (dHMN).
Methods
A 2-year-old boy was diagnosed with arthrogryposis multiplex congenital, severe skeletal abnormalities, torticollis, vocal cord paralysis and diminished lower limb movement. Whole exome sequencing was performed on the proband and family members. Structure modeling and functional studies were performed to validate pathogenicity of the identified variant.
Results
Whole exome sequencing revealed a biallelic homozygous mutation in the TRPV4 gene (c.281C>T; p.S94L). The identification of a novel recessive mutation in TRPV4 extends the spectrum of mutations in recessive forms of the TRPV4-associated disease. Structural modeling and functional studies were performed on p.S94L and other previously identified TRPV4 variants in different protein domains. Structural modeling suggests that the p.S94L mutation is in the disordered N-terminal region proximal to important regulatory binding sites for phosphoinositides and for PACSIN3, which could lead to alternations in trafficking and/or channel sensitivity. Functional studies show that p.S94L reduces TRPV4 protein stability and therefore involves a loss-of-function mechanism.
Conclusion
This study identifies a novel biallelic mutation in TRPV4 as a cause of the recessive form of congenital form of distal hereditary motor neuropathy (dHMN). Glossary dHMN = distal hereditary motor neuropathy; HMSN = hereditary motor and sensory neuropathy; HSAN = hereditary sensory and autonomic neuropathy; SPSMA = scapuloperoneal spinal muscular atrophy; CSMAA = congenital spinal muscular atrophy and arthrogryposis; CMT = Charcot-Marie-Tooth diseases; PBD = phosphoinositidebinding domain; PRR = proline-rich region; PIP2 = phosphatidylinositol biphosphate; FDAB = Familial digital arthropathy-brachydactyly Hereditary neuropathies are a clinically and genetically heterogeneous group of diseases with an estimated prevalence of 1:2500. Clinical manifestations of hereditary neuropathies include slow progressive distal weakness and muscle wasting with or without sensory loss. Hereditary neuropathies are classified in to three broad categories on the basis of clinical phenotype. Charcot-Marie-Tooth disease or hereditary motor and sensory neuropathy (HMSN) typically exhibits involvement of both motor and sensory systems, hereditary sensory and autonomic neuropathy (HSAN) involves sensory deficits and/or autonomic dysfunction, and distal hereditary neuropathy (dHMN) predominately involves motor deficits. These groups can be further classified into many subtypes depending on electrophysiological criteria, pathological defects, mode of inheritance and molecular genetic defects. These diseases are genetically highly heterogeneous with mutations in at least 80 different genes associated with these subtypes 1, 2 . Despite this significant progress, 30-70% of people affected with neuropathies do not have a genetic diagnosis due to clinical and genetic heterogeneity.
Some of disease symptoms can be controlled with generic drugs. However, the identification of the underlying genetic lesion is necessary for accurate disease prognosis, management and family planning, and may ultimately lead to personalized treatments.
Mutations in the TRPV4 (transient receptor potential vanilloid 4) cation channel gene are a rare cause of dominant inherited axonal neuropathies and skeletal dysplasias 3, 4 . in patients with neuropathies. However, functional validation of pathogenicity for many of these variants is still lacking, thus preventing a conclusive genetic diagnosis in these patients. To improve the genetic diagnosis of patients affected with neuropathies, we are using whole exome sequencing (WES) combined with functional validation studies to establish the pathogenicity of variants identified by WES. This work has identified the first TRPV4 homozygous mutation in a patient presented with congenital spinal muscular atrophy and arthrogryposis. Follow-up functional studies reveal distinct disease mechanisms for different TRPV4 variants and provide novel insights that may inform future therapeutic strategies for these patients.
Results

Clinical Presentation
The male proband was born to unrelated healthy parents of Puerto Rican decent after 37 weeks of gestation ( Fig. 1A ). He has a healthy sister. The proband was delivered by Caesarian section due to breech position and arthrogryposis multiplex congenita on ultra-sound. At birth, the proband exhibited a right clubfoot, a left congenital vertical talus, and bilateral flexion deformities of the knees. In addition to lower extremity skeletal deformities, the proband exhibited torticollis, vocal cord paralysis, hypotonia and mild head lag. At age 2 years, the proband could sit independently and walk on his knees. However, he was unable to stand or walk independently. Except for lower limb movement, the proband has normal speech, fine motor and gross motor skills in his upper limbs, normal hearing and visual development. Electromyography (EMG) revealed a motor axonopathy with coexisting denervation and reinnervation changes.
Whole Exome Sequencing (WES)
Whole exome sequencing was performed on the proband and parents. The presence of a single affected male individual in this family is consistent with autosomal recessive inheritance, X-linked inheritance or with a dominant de novo mutation.
Therefore, pedigree and population based filtering was performed to identify potentially damaging homozygous, X-linked, compound heterozygous and de novo variants. We only considered rare coding and splice variants that have <0.1-1 % allele in general healthy population in the gnomAD database (gnomad.broadinstitute.org) depending on dominant or recessive inheritance mode, that is consistent with the prevalence of the disease. In total, 15 potential genes carried a variant ( Supplementary Table 1 ), that were further prioritized using our knowledge-based and crowdsourcing pipeline recently PACSIN3 enhances TRPV4 trafficking to the cellular membrane. PIP2 binding enhances TRPV4 responses to several stimuli whereas PACSIN3 decreases responses to these same stimuli via an antagonistic interaction between two key regulators that is likely mediated through PACSIN3-mediated structural rearrangements of the PRR 7, 9 . Therefore, our structural modeling suggests that the p.S94L mutation could potentially affect the regulation and/or sensitivity of TRPV4.
Structural Model
Functional Modeling of TRPV4 Variants
Functional studies have shown a gain-of-function mechanism for previously known dominant mutations in TRPV4 10 . To validate the pathogenicity of the p.S94L variant, functional studies were performed by analyzing the stability and localization of the mutant protein. To compare the magnitude of the functional deficits, known neuropathycausing p.R269C and p.R315W TRPV4 mutants were analyzed in parallel. In addition, a mutation p.T701I has been reported as a cause of neuropathy. p.T701I is localized to the transmembrane domain S6 helix (Fig. 2) , near the vanilloid-binding site in the homologous ion channel TRPV1. 11 Currently, there are no functional studies establishing the pathogenicity of this variant in human diseases or TRPV4 protein functions. Therefore, we investigated the effect of p.S94L, p.R269C, p.R314W and p.T701I on the stability and subcellular localization of TRPV4. To investigate the effect of different variants on protein stability, TRPV4-WT and mutant constructs were transiently expressed in HEK293T cells and expression was analyzed by western blot.
Protein analysis by western blot showed an absence of p.S94L protein as well as reduced levels of p.R269C and p.R315W. In contrast, p.T701I exhibited levels of protein expression similar to those of wild-type TRPV4. To examine the sub-cellular localization of p.S94L and other mutants, immunofluorescence analyses were performed. Wild-type TRPV4 primarily localized to the plasma membrane as has been reported for endogenous TRPV4 protein. p.R269C and p.R315W also exhibited localization to the plasma membrane. Interestingly, the p.T701I mutant protein showed a perinuclear localization pattern, and in contrast to wild-type protein, no protein was detected on the plasma membrane. Consistent with its lack of expression by western blot, no staining for pS94L was observed by immunostaining. this as a crucial amino acid. Here, we demonstrate that TRPV4 p.S94L severely affects protein stability, thereby impairing TRPV4 localization to the plasma membrane, and consequently its function. This is the first report of loss-of-function in the TRPV4 cation channel as a cause of disease in a human patient. Previous work has identified reduced stability of many dominant variants in the intracellular ankyrin-repeat domain of TRPV4 12 . A recent study also identified biallelic heterozygous mutations located in the C-terminus of the TRPV4 channel in two siblings with neuropathy associated with severe intellectual disability 13 . These mutant proteins demonstrated normal membrane localization; however, they showed reduced channel function. In contrast, the p.S94L variant resulted in a complete absence of the mutant protein and hence an elimination of TRPV4 channel activity leading to a severe phenotype in the proband.
Discussion
Interestingly, Trpv4 knockout mice are viable and fertile, but exhibit an increased bladder capacity due to an impaired stretch sensor in the bladder wall, thicker bones due to impaired osteoclast differentiation, reduced water intake due to altered osmosensation, compromised vascular endothelial function and some sensory defects, such as hearing alteration, impaired sensation and compromised pain sensing. As mammalian genomes contain six TRPV genes, a lack of severity of phenotype in mice knockout models could be due to functional redundancy of these channels in mice. The p.S94L mutation is located in the N-terminal intracellular region upstream of the ankyrin repeat domains. Previous studies have shown that dominant mutations in this region result in neuropathy in affected individuals. However, the proband's parents who are heterozygous for the TRPV4 p.S94L variant did not exhibit any phenotype, as well as 6 heterozygous individuals are reported in the gnomAD database. This could be due to reduced channel function as opposed to the gain-of-function mechanism believed to underlie other TRPV4 mutations. Nonetheless, many TRPV4 variants exhibit reduced penetrance in adult carriers and for this reason, the parents of the proband were counseled to routine follow up in neurology clinic. Interestingly, most human diseasecausing variants studied in this work exhibited a reduced protein stability, whereas the p.T701I variant altered the cellular localization of TRPV4 protein, from plasma membrane to the perinuclear area. This mis-localization may result in altered calcium channel function in affected patients. Together, these results demonstrate that different mutations in TRPV4 affect the channel function by different mechanisms.
Understanding the functional alterations in mutant TRPV4 channels is essential not only for determining the pathogenicity of novel variants, but also for the design of specific therapies as both agonists and antagonists of TRPV4 channels are available.
Materials and Methods
Patient consents and standard protocol approvals
The proband, both parents and the affected sibling were enrolled and informed consent was obtained from participants in accord to an Institutional Review Board approved study at Boston Children's Hospital and Brigham and Women's Hospital. Sequencers at Lab Corp. FASTQs generated from exome sequencing were filtered and aligned, and variants were filtered and annotated, as previously described 5 . In short, first we apply agnostic filtering, and we use pedigree based inheritance mode filtering for de novo , and recessive variants, as well as filter for rare variants only based on large population databases (gnomAD, gnomad.broadinstitute.org). In the second step, we apply several knowledge-based filters on the genes (e.g. known functional and disease associations, expression level data, model organism data) and on the variants (e.g. evolutionary conservation, structural constraints etc.). Finally, the variants were prioritized during a crowdsourcing case conference of interdisciplinary audience. 5 To validate the TRPV4 variant, PCR products for the proband, unaffected sibling and parents were analyzed by standard Sanger sequencing (Dana-Farber/Harvard Cancer Center DNA Sequencing Facility).
Whole-exome sequencing
In silico modeling of TRPV4 mutations
TRPV4 mutations were mapped onto the cryoEM structure of Xenopus tropicalis TRPV4 (PDB ID: 6bjj) 6 after aligning the XtTRPV4 and human TRPV4 sequences using Clustal Omega. Figure 2 was generated using PyMOL (Schrodinger).
Cloning of mutant constructs
To generate TRPV4 mutant plasmids, p.S94L, p.R315W and & p.T701I variants were incorporated into TRPV4 cDNA using Q5 site-directed mutagenesis kit (New England Biolabs). The mutagenesis primer sequences were: S94L forward: 5 '-TAT GAG TCC   TTG GTG GTG CCT-3', S94L reverse: 5'-TAG GGT GGA CTC CAG CAG-3', R315W   forward: 5'-GGC GGA CAT GTG GCG CCA GGA-3', R315W reverse: 5'-TTC TTG TGG   GGG TTC TCC GTC AGGT-3', T701I forward: 5'-CTG CTG GTG ATC TAC ATC ATC- 3', T701I reverse: 5'-GAT GAT GAA GAC CAC GGG-3'.
Cell Culture and Transfection
Human HEK293T cells were cultured in growth medium consisting of DMEM supplemented with 10% fetal bovine serum. Cells were transfected with plasmid DNAs, including control empty vector, using Lipofectamine 3000 (Life Technologies) and harvested after 48 hours for RNA and protein isolation.
Western Blot and Immunofluorescence Analysis
Forty-eight hours after transfection, cell lysates were prepared in RIPA buffer (Thermofisher Scientific) and western blot were performed according to standard protocols. M2 anti-Flag antibody (Sigma F1804, 1:1000) was used to detect TRPV4tagged proteins. GAPDH (Abcam 8254, 1:10,000) was used as a loading control.
Densitometric analysis was performed with imageJ (https://imagej.nih.gov/ij/) For immunofluorescence, HEK293T cells were plated in 8-chambered slides and transfections were performed as described above. Twenty-four hours after transfection, cells were fixed in 4% paraformaldehyde and immunofluorescence was performed as described previously 14 . M2 anti-Flag antibody (Sigma, 1:250) and sodium potassium 
